Pharma Welcomes UK Incentive Plan To Tackle AMR
Executive Summary
There has been an enthusiastic response from industry to the news that NICE and NHS England are to explore a new payment model that pays pharmaceutical companies based on how valuable their medicines are to the country's health service, rather than on the quantity of antibiotics sold.
You may also be interested in...
How To Pay For AMR Drugs: Pull, Not Just Push
Encouraging companies to develop new antimicrobials requires a new way of thinking about value assessment. A UK five-year AMR plan takes this into consideration.
Merck And The 'Strange Business' Of Antibiotics
Antibacterials have been part of Merck's mission for decades, despite the market challenges, and it's expecting two new approvals this year. Infectious disease VP Joan Butterton talks about tackling those challenges and incentives that may help the industry address antimicrobial resistance.
Destiny Pharma's XF-73 Being Studied For Diabetic Foot Ulcers, Burns Too
One year after its IPO, UK-based Destiny Pharma's CEO tells Scrip it's on track with US development of its lead antimicrobial asset XF-73 for prevention of post-operative infections and will also develop a new formulation to treat infections in diabetic foot ulcers and burn wounds.